Amgen Inc. said Tuesday that, thanks to...

Amgen Inc. said Tuesday that, thanks to gains in the sale of its key Epogen drug, it earned $108.6 million, or 78 cents per share, in the first quarter of 1995, up 16% from $93.5 million, or 66 cents per share, in the year-earlier period. Amgen’s results were at the low end of expectations, and its share price fell 44 cents on Nasdaq to $67.50.

Epogen, used to restore red blood cells in AIDS patients and people with kidney failure, gained 21% in sales in the quarter. Neupogen, which restores white blood cells in cancer patients undergoing chemotherapy, gained 17%.